SENS Earnings Prediction
The chart below shows how SENS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SENS sees a -0.35% change in stock price 10 days leading up to the earnings, and a -8.08% change 10 days following the report. On the earnings day itself, the stock moves by -0.63%. This data can give you a slight idea of what to expect for the next quarter's release.
SENS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
4.26M
-30.08%
-12.37%
Gross Margin
-95.03%
-594.43%
-1650.24%
Operating Margin
-535.94%
71.78%
33.76%
Net Margin
-562.42%
42.27%
34.87%
EPS
-0.04
-0.00%
33.33%
No Data Available
SENS Earnings Analysis
Senseonics Holdings, Inc. Corporation (SENS.A) Earnings Conference Call
Positive
Continuous Glucose Monitor Approval: 1. FDA Approval for Eversense 365: Received FDA approval for Eversense 365, the world's first and only one-year continuous glucose monitor, marking a significant milestone for the company.
Historic Lead Surge: 2. Record Lead Generation: In the first week post-launch, the company experienced the highest influx of leads in its history, indicating strong market interest in Eversense 365.
Partnership with Mercy Health: 3. Collaboration with Mercy Health System: Mercy, the first hospital system to adopt Eversense 365, has over 30,000 patients who could benefit from the CGM, potentially improving patient outcomes and reducing diabetes care costs.
Expanded Prescriber Network: 4. Increased Prescriber Network: Ascensia has established a network of approximately 800 certified doctors and nurse practitioners to support the U.S. launch of Eversense 365, enhancing patient access and adoption.
Future Revenue Projections: 5. Projected Revenue Growth: The company expects full-year 2024 global net revenue to be approximately $22 million, with plans to double U.S. new patient starts and increase the global installed base by about 50% compared to 2023.
Negative
Revenue Decline Analysis: 1. Declining Revenue: Third quarter net revenue was $4.3 million, down from $6.1 million in the prior year period, primarily due to inventory dynamics associated with the 365-day product launch.
Gross Loss Decline: 2. Gross Loss: The company reported a gross loss of $4.1 million in Q3 2024, a significant decline from a gross profit of $1.2 million in the same period last year, driven by one-time charges related to the product transition.
Operating Loss Increase: 3. Increased Operating Loss: For the nine months ended September 2024, the operating loss was $22.8 million, compared to $19 million in the same period of 2023, attributed to inventory write-offs during the transition to the 365-day product.
Rising Operating Expenses: 4. High Operating Expenses: Selling, general, and administrative expenses rose to $8.3 million in Q3 2024, up from $7.4 million in the prior year, primarily due to increased personnel and consulting costs.
Cash and Debt Analysis: 5. Cash Position and Debt: As of September 30, 2024, the company had $74.8 million in cash and short-term investments, but also carried $55.9 million in debt and accrued interest, indicating a strained cash position amidst ongoing financial challenges.
SENS FAQs
How does SENS typically perform around its earnings report dates?
Is Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SENS Earning Call Sentiment
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SENS.A
8.25%Positive
The earnings call highlighted several concerns: declining revenue, gross loss due to transition costs, and lack of guidance for 2025, which suggests uncertainty. The Q&A revealed vague responses about growth and supply chain challenges, indicating potential risks. The absence of a shareholder return plan and significant restructuring further dampen sentiment. While there are optimistic growth prospects, the immediate financial health and operational risks suggest a negative stock price reaction in the short term.